Canesflor Vaginal Probiotics | Helps Prevent Recurrence of Vaginal Infections such as Thrush | Clinically Proven - 10 Count (Pack of 1)

Product Information

Speak to your healthcare practitioner for more information about supplementation. Make sure to always read the label and use only as directed. If symptoms persist, see your healthcare practitioner. Boris et al. found that the adherent properties G. vaginalis were similarly affected by Lactobacillus acidophilus [ 73].

Using a single strain or mixtures of Lactobacillus strains, especially vaginal L. crispatus, could have many benefits. It avoids the risk of introducing other vaginal bacteria related to vaginosis or infections, such as G. vaginalis and Prevotella species. Once the Lactobacillus strains colonize, the produced lactic acid and bacteriocins could lower vaginal pH, inhibit BV-related pathogens, and potentially prevent BV recurrence in the long term 9, 10, 11, 14. It is easier to culture single bacterial strains in large batches under controlled standard conditions. It is also cheaper for clinical use and prevents the possibility of transferring cells and untested organisms from donor women, as in VMT. Bacterial vaginosis (BV) is one of the most common diseases in women of reproductive age [ 1]. In China, the prevalence of BV ranged from 5.9% to 15.4% [ 2]. However, this number was 16.3%–29.2% in the United States [ 3], and reached up to 50% in southern and eastern Africa [ 4]. Despite this being a mild disease, patients with BV may suffer from a higher risk of reproductive tract infections and adverse pregnancy outcomes [ 5, 6, 7]. vaginal douche containing > 1.0 × 10 8 colony-forming units/mL of L. acidophilus ( n = 32), or no treatment

Most Read Articles

To summarize, most of the current BV clinical trials did not use Lactobacillus species from the vaginal tract. These data collectively indicate that L. crispatus could be of potential use for BV treatment and that a rigorous pre-clinical screening strategy needs to be applied to identify the best strains that can maximize adaptiveness and colonization in the vaginal environment. The proper Lactobacillus species from a vaginal microbiome should also be tested in large, randomized, placebo-controlled cohorts. Consideration 2: administration method After completing metronidazole treatment, patients received placebo and vaginal tablets containing probiotics, respectively (n=250). Did you know that just like our gut, which is populated by beneficial bacteria, so too the urogenital tract of women contains valuable microbiota? 1 These are mostly of the Lactobacillus species (spp. or group) of bacteria, and are responsible for maintaining the health of the vaginal tract. 2 Probiotics containing these beneficial bacteria can be taken orally, but may also be applied locally in a ‘pessary’ form, and can be helpful in maintaining the balance of good bacteria in the vaginal tract. 1-3 Borges S, Silva J, Teixeira P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 2014;289(3):479-489. Larsson, P.-G., Stray-Pedersen, B., Ryttig, K. R. & Larsen, S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Women’s Health 8, 3 (2008).

DI Pierro F., Criscuolo A. A., Dei Giudici A., Senatori R., Sesti F., Ciotti M., et al.. (2021). Oral administration of lactobacillus crispatus M247 to papillomavirus-infected women: results of a preliminary, uncontrolled, open trial. Minerva Obstet Gynecol 73 ( 5), 621–631. doi: 10.23736/s2724-606x.21.04752-7 Coleman J. S., Gaydos C. A. (2018). Molecular diagnosis of bacterial vaginosis: an update. J. Clin. Microbiol. 56 ( 9), e00342–18. doi: 10.1128/jcm.00342-18Mastromarino, P. et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin. Microbiol Infect. 15, 67–74 (2009).

One aspect of the high rate of BV recurrence after therapy could be due to biofilm persistence 81. Biofilm formation enhances the endurance of BV-related bacteria against antibacterial regimens from beneficial vaginal microbes or antibiotic treatment 82. G. vaginalis is considered to be the key player in biofilm formation by adhering to the surface of vaginal epithelial cells and allowing the attachment of other species, thus leading to the formation of “clue cells,” which have been used in the clinical diagnosis of BV 83, 84. Bioproducts, such as anti-biofilm or antimicrobial peptides that inhibit BV-associated bacterial growth and biofilm formation, could be a future replacement for antibiotic treatment to achieve higher precision and fewer side effects 31, 85, 86. Biofilm-disrupting agents, such as intravaginal boric acid enhanced with ethylenediaminetetraacetic acid (TOL-463) and amphoteric tenside (WO3191), are being investigated to determine their role in BV treatment (NCT03930745, NCT02687789) 87, 88. Another biofilm-disrupting agent example is a pHyph, a vaginal pessary containing glucono-delta-lactone and sodium gluconate. In a recent study, it was shown that pHyph has the potential to restore a normal pH and resolve clinical BV symptoms 89. Gordillo Altamirano, F. L. & Barr, J. J. Phage therapy in the postantibiotic Era. Clin Microbiol Rev.s 32, e00066–18 (2019).Chen T., Xia C., Hu H., Wang H., Tan B., Tian P., et al.. (2021). Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination. Int. J. Antimicrob. Agents 57 ( 3), 106277. doi: 10.1016/j.ijantimicag.2021.106277